Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 3:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 660 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Migraine
Interventions
n-VNS
Device
Lead sponsor
ElectroCore INC
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
San Francisco, California • New York, New York • The Bronx, New York
Conditions
Episodic Migraine
Interventions
AMG334, Oral Prophylactic
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Stanford, California • New Haven, Connecticut • Stamford, Connecticut + 17 more
Conditions
Migraine
Interventions
Music and Imagery
Behavioral
Lead sponsor
Richard L. Roudebush VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Active, not recruiting Phase 2 Interventional

Migraine Manager (R01)

NCT04567355
Conditions
Migraine, Migraine Disorders
Interventions
Migraine Manager
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Headache, Migraine, Multiple Sclerosis
Interventions
RELAXaHEAD app, Monitored Usual Care (MUC)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Recruiting Not applicable Interventional Accepts healthy volunteers

Objectively Diagnose and Monitor Treatment of Light Sensitivity

NCT03694626
Conditions
Photophobia, Traumatic Brain Injury, Migraine
Interventions
Pupillography, Ocular Coherence Tomography (OCT), Wrist-watch sensor device, Videography, Electrophysiology
Device
Lead sponsor
Randy Kardon
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Migraine Disorders
Interventions
Combination Tablet of Treximet (sumatriptan/naproxen sodium)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 17 Years
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
77
States / cities
Gilbert, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 72 more
Completed Phase 4 Interventional Results available

Sphenopalatine Ganglion Blocks RCT

NCT03666663
Conditions
Migraine
Interventions
Lidocaine, Bupivacaine, Ropivacaine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Conditions
Migraine
Interventions
Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
30
States / cities
Tempe, Arizona • Colton, California • Los Angeles, California + 27 more
Conditions
Migraine
Interventions
Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
109
States / cities
Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more
Active, not recruiting Phase 4 Interventional

Nerivio Efficacy Under High-Frequency Use

NCT07336056
Conditions
Migraine
Interventions
Nerivio (REN device)
Device
Lead sponsor
Theranica
Industry
Eligibility
8 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Rimegepant, Placebo, Sumatriptan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more
Conditions
Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
12 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Migraine, Migraine With or Without Aura
Interventions
Meditation
Behavioral
Lead sponsor
Maharishi International University
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Episodic Migraine Headache
Interventions
LBR-101 High Dose, LBR-101 Low Dose, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
63
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Prochlorperazine Single Dose PK Study

NCT00610727
Conditions
Migraine
Interventions
Prochlorperazine 0.5 mg IV over 5 sec, Inhaled prochlorperazine 0.625 mg, Inhaled prochlorperazine 1.25 mg, Inhaled prochlorperazine 2.5 mg, Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Inhaled placebo, Prochlorperazine 10 mg IV over 5 sec
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Conditions
Migraine
Interventions
Erenumab, Placebo, PACAP-38 Challenge Agent
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Anaheim, California
Completed No phase listed Observational

A Complex Contraception Registry

NCT02219269
Conditions
Diabetes, Cardiovascular Disease, Epilepsy, Migraine, Neurological Disorders, Cancer, Bariatric Surgery Candidate, Organ or Tissue Transplant; Complications, Lupus Erythematosus, Systemic, Other Hematologic Conditions, Other Venous Embolism and Thrombosis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 2 more
Completed Phase 2 Interventional Results available

A Study of LY3451838 in Participants With Migraine

NCT04498910
Conditions
Migraine
Interventions
LY3451838, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Phoenix, Arizona • Stamford, Connecticut • Ocala, Florida + 6 more
Conditions
Migraine
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Aliso Viejo, California • Naperville, Illinois • Grand Island, Nebraska
Conditions
Headache, Migraine
Interventions
Ubrogepant 50 MG [Ubrelvy], Ubrogepant 100 MG [Ubrelvy]
Drug
Lead sponsor
Chicago Headache Center & Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Naperville, Illinois
Conditions
Migraine Headache
Interventions
High Dose Psilocybin, Low Dose Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Acute Migraine Headache
Interventions
prochlorperazine and benadryl IV, Imitrex SubQ, saline IV
Drug
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Portsmouth, Virginia
Completed Phase 2Phase 3 Interventional Results available

Low-dose Propofol for Pediatric Migraine

NCT01604785
Conditions
Migraine Headache
Interventions
Propofol, Standard Treatment
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
7 Years to 18 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Portland, Oregon